Back to top
more

Checkpoint Therapeutics (CKPT)

(Delayed Data from NSDQ)

$1.43 USD

1.43
541,824

+0.01 (0.70%)

Updated Apr 26, 2024 04:00 PM ET

After-Market: $1.44 +0.01 (0.70%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.20%
2Buy18.04%
3Hold9.52%
4Sell5.20%
5Strong Sell2.60%
S&P50011.13%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

NA Value NA Growth NA Momentum NA VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 30% (76 out of 252)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Brokerage Reports

0 items in cart

Checkpoint Therapeutics, Inc. [CKPT]

Reports for Purchase

Showing records 21 - 40 ( 47 total )

Company: Checkpoint Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 21

08/26/2021

Industry Report

Pages: 10

Key 2021 Universe Catalysts to Focus On as Market Turbulence Continues

Provider: H.C. Wainwright & Co., Inc.

Analyst: PANTGINIS J

Price: 25.00

Research Provided by a Third Party

Company: Checkpoint Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 22

08/06/2021

Company Report

Pages: 9

2Q21 Results; Positive Regulatory Outlook for Assets; Cosibelimab Approaching First Endgame

Provider: H.C. Wainwright & Co., Inc.

Analyst: PANTGINIS J

Price: 25.00

Research Provided by a Third Party

Company: Checkpoint Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 23

05/12/2021

Company Report

Pages: 8

Next Step Complete as We Near First Endgame for Cosibelimab; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: PANTGINIS J

Price: 25.00

Research Provided by a Third Party

Company: Checkpoint Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 24

03/15/2021

Company Report

Pages: 8

2020 Results; Cosibelimab Leading to a Transformational Year

Provider: H.C. Wainwright & Co., Inc.

Analyst: PANTGINIS J

Price: 25.00

Research Provided by a Third Party

Company: Checkpoint Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 25

01/13/2021

Company Report

Pages: 9

Cosibelimab Quickly Moving to First Endgame; Potential Suitors Should be Excited

Provider: H.C. Wainwright & Co., Inc.

Analyst: PANTGINIS J

Price: 25.00

Research Provided by a Third Party

Company: Checkpoint Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 26

11/09/2020

Company Report

Pages: 6

Next Cosi Pivotal Taking Nice Shape off of SITC Data; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: PANTGINIS J

Price: 25.00

Research Provided by a Third Party

Company: Checkpoint Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 27

09/29/2020

Company Report

Pages: 7

ESMO Data Shine; Tipping Point Here in Our Belief; Target Increased to $17

Provider: H.C. Wainwright & Co., Inc.

Analyst: PANTGINIS J

Price: 25.00

Research Provided by a Third Party

Company: Checkpoint Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 28

08/06/2020

Company Report

Pages: 7

2Q20 Results; Cosibelimab Interim Data at ESMO to Further De-Risk Thesis

Provider: H.C. Wainwright & Co., Inc.

Analyst: PANTGINIS J

Price: 25.00

Research Provided by a Third Party

Company: Checkpoint Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 29

06/25/2020

Company Report

Pages: 7

It''s Crunch Time; Major Data Update Approaching for Already De-Risked Thesis

Provider: H.C. Wainwright & Co., Inc.

Analyst: PANTGINIS J

Price: 25.00

Research Provided by a Third Party

Company: Checkpoint Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 30

03/12/2020

Company Report

Pages: 7

2019 Results; Cosibelimab Pivotal Study Pushed Forward; BLA Targeted for Late 2021

Provider: H.C. Wainwright & Co., Inc.

Analyst: PANTGINIS J

Price: 25.00

Research Provided by a Third Party

Company: Checkpoint Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 31

01/16/2020

Company Report

Pages: 6

Important Visibility: Positive FDA View on Cosibelimab Study with BLA in 2021

Provider: H.C. Wainwright & Co., Inc.

Analyst: PANTGINIS J

Price: 25.00

Research Provided by a Third Party

Company: Checkpoint Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 32

11/11/2019

Company Report

Pages: 7

SITC Cosibelimab Update All About Target Engagement; 3Q19 Results; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: PANTGINIS J

Price: 25.00

Research Provided by a Third Party

Company: Checkpoint Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 33

09/30/2019

Company Report

Pages: 7

Cosibelimab Data Continue to Support Its Regulatory Path; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: PANTGINIS J

Price: 25.00

Research Provided by a Third Party

Company: Checkpoint Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 34

08/09/2019

Company Report

Pages: 6

2Q19 Results; Data Updates by YE Should Provide Nice Visibility Boost; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: PANTGINIS J

Price: 25.00

Research Provided by a Third Party

Company: Checkpoint Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 35

05/13/2019

Company Report

Pages: 8

1Q19 Results; Pivotal Times Coming Soon; Data Certainly Supportive in Our Eyes; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: PANTGINIS J

Price: 25.00

Research Provided by a Third Party

Company: Checkpoint Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 36

05/01/2019

Company Report

Pages: 12

Time to Get Real "Cosi" With Cosibelimab; Data Impress as Eyes Turn to Pivotal and BD Efforts; Target Raised to $15

Provider: H.C. Wainwright & Co., Inc.

Analyst: PANTGINIS J

Price: 25.00

Research Provided by a Third Party

Company: Checkpoint Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 37

03/15/2019

Company Report

Pages: 6

2018 Results; Assets Going Pivotal Soon; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: PANTGINIS J

Price: 25.00

Research Provided by a Third Party

Company: Checkpoint Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 38

01/14/2019

Company Report

Pages: 6

Defining Registration End Games; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: PANTGINIS J

Price: 25.00

Research Provided by a Third Party

Company: Checkpoint Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 39

11/02/2018

Company Report

Pages: 6

3Q18 Results; Driving Hard Towards CK-101 Pivotal Study; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: PANTGINIS J

Price: 25.00

Research Provided by a Third Party

Company: Checkpoint Therapeutics, Inc.

Industry: Unclassified

Record: 40

09/06/2018

Daily Note

Pages: 4

Checkpoint''s First Ever Clinical Data Impress; Setting Stage for 2019 Pivotal Study

Provider: H.C. Wainwright & Co., Inc.

Analyst: PANTGINIS J

Price: 10.00

Research Provided by a Third Party